

# UC Irvine

## UC Irvine Previously Published Works

**Title**

Treatment of infantile spasms: the ideal and the mundane.

**Permalink**

<https://escholarship.org/uc/item/2924d90w>

**Journal**

Epilepsia, 44(8)

**ISSN**

0013-9580

**Author**

Baram, Tallie Z

**Publication Date**

2003-08-01

**DOI**

10.1046/j.1528-1157.2003.44086.x

**Copyright Information**

This work is made available under the terms of a Creative Commons Attribution License, available at <https://creativecommons.org/licenses/by/4.0/>

Peer reviewed

Published in final edited form as:

*Epilepsia*. 2003 August ; 44(8): 993–994.

## Treatment of Infantile Spasms: The Ideal and the Mundane

**Tallie Z. Baram**

Departments of Pediatrics, Anatomy/Neurobiology and Neurology, University of California at Irvine. Irvine, California U.S.A

Over 150 years after the description of infantile spasms (IS, 1), fifty years after the delineation of hypsarrhythmia (2), and forty years after the coining of the term “west syndrome” (3), there is little progress in understanding and effectively treating this disorder.

This may not be surprising, because there is little consensus about most features of this enigmatic syndrome: is it a generalized seizure disorder, as classified by the ILAE (4), or focal seizures arising from “hidden” limbic (5) or brainstem (6) regions? Are the spasms truly seizures, or does the pervasive hypsarrhythmia signify a state of virtual status epilepticus? Some of the least defined aspects of infantile spasms remain in the treatment arena. Indeed, even the need for treatment has been debated (7), particularly in view of the fact that IS seems to remit spontaneously in most affected infants (8, but see 9). However, a broad consensus does exist on the merits of therapy for IS. This is particularly true because of often clear regression of an affected infant—whether or not his/her development had been normal prior to the onset of spasms (10,11). Further, successful treatment may lead to dramatic improvements in cognition and function. Therefore, a quest for effective, well tolerated therapies for IS has been the Golden Fleece of the clinical Argonauts in the field.

The relative ineffectiveness of conventional anticonvulsants for IS had been established by the mid 20th century (reviewed in 10,11). The pioneering work of Sorel (12) suggested that the neuropeptide corticotropin (ACTH), acting directly within the brain (13–15) might suppress IS. Early anecdotal clinical success with ACTH (12,16) was confirmed by blinded controlled studies, although the rate of ACTH efficacy varied from ~40 to 88% (17,18). Whereas the rapid and robust effects of ACTH in eradicating IS and the hypsarrhythmia reported in these studies were impressive, the underlying mechanisms remained unclear. Actions directly within the brain were suggested by concurrent work in animals (13,19), but the lack of efficacy of analogs that do not release endogenous steroids (14,15) led to the conclusion that ACTH acted on IS by releasing endogenous glucocorticoids, a view supported by the (more limited) efficacy of the latter hormones (19,20). The notion that ACTH and glucocorticoids share a hormonal action that alters immune (20), stress (21), inflammatory or other derangements in IS became prevalent, to the point that both classes of compounds are commonly referred to as “steroids” (20). In addition, the rationale for the use of one is often based on efficacy and side effects of the other.

More recently, unique mechanisms of action of ACTH, entering the CNS and acting on melanocortin receptors (MCRs) to reduce an excitatory neuropeptide in limbic structures has been put forth (22). These data suggest that analogs of ACTH that bind MCRs but do not release steroids might constitute the longed-for Golden Fleece—the successful, hypothesis-driven therapy that is free of severe systemic side effects of ACTH and high dose steroids (21,22).

Whereas this ethereal goal might be realized in the future, much effort has been directed over the past 50 years to evaluate the role of available anticonvulsants for IS, and each new promising drug has been tested on these seizures (e.g., 23,24). The discovery of vigabatrin in particular raised tremendous hope: The drug controlled the spasms and improved or

eliminated hypsarrhythmia initially in uncontrolled (25), then in larger controlled trials (26,27), and particularly in IS associated with tuberous sclerosis (28). Whereas the precise efficacy of vigabatrin has not been fully defined (27,29), the medication has rapidly gained prominence as a key step forward in the Argonauts' quest for optimal IS therapy.

The use of vigabatrin for IS has more recently been significantly curtailed by the emergence of apparently irreversible retinal changes and altered peripheral vision upon its use. While these side effects have diminished the likelihood of the drug's approval in the U.S., vigabatrin remains an important mainstay in the treatment of IS in Europe, together with earlier anticonvulsants with some established efficacy, such as nitrazepam (30). In addition, among the emerging crop of new anticonvulsant medications, none has shown exceptional efficacy for the disorder. Based on all of this, how should a clinician treat an infant with IS?

Whereas the optimal therapy for this disorder remains elusive, the paper by Capovilla and colleagues in this issue describes some of the approaches that are being utilized in Europe. The paper discusses the use of nitrazepam and vigabatrin, and addresses specifically the issue of treatment duration: when is it safe to discontinue the medication? Using a collaborative multicenter approach, the authors demonstrate that at least in some infants, treatment may be stopped, without seizure recurrence, after several months. This information should be significantly helpful to clinicians who are facing these issues.

Other related questions continue unanswered: How many infants with IS were seen? How many were treated with these drugs and did not respond, or were excluded for a variety of reasons?—in other words, what is the likelihood that a clinician treating an infant with nitrazepam or vigabatrin will be successful in controlling the spasms and in discontinuing therapy. These answers are still shrouded in mists, as are those for the cardinal questions of which drugs to use and how to evaluate their efficacy. Still, while the optimal therapy for IS, based on the understanding of its pathophysiology, remains our Golden Fleece, the paper by Capovilla et al., provides useful hints for practical management of the disorder.

## References

1. West WJ. On a peculiar form of infantile convulsions. *Lancet*. 1841; 1:724–5.
2. Gibbs, FA.; Gibbs, EL. *Epilepsy*. Vol. 2. Cambridge, MA: Addison-Wesley; 1952. Atlas of electroencephalography.
3. Eling P, Renier WO, Pomper J, Baram TZ. The mystery of the doctor's son, or the riddle of West Syndrome. *Neurology*. 2002; 58:953–5. [PubMed: 11914414]
4. Commission on classification and terminology of the International League against Epilepsy. *Epilepsia*. 1989; 30:389–99. [PubMed: 2502382]
5. Acharya JN, Wyllie E, Luders HO, Kotagal P, Lancman M, Coelho M. Seizure symptomatology in infants with localization-related epilepsy. *Neurology*. 1997; 48:189–96. [PubMed: 9008517]
6. Hrachovy RA, Frost JD. Infantile spasms. *Pediatr Clin North Am*. 1989; 36:311–29. [PubMed: 2538796]
7. Lerman P, Kivity S. The efficacy of corticotropin in primary infantile spasms. *J Pediatr*. 1982; 101:294–6. [PubMed: 6284904]
8. Hrachovy RA, Glaze DG, Frost JD Jr. A retrospective study of spontaneous remission and long-term outcome in patients with infantile spasms. *Epilepsia*. 1991; 32:212–4. [PubMed: 1848513]
9. de Menezes MA, Rho JM. Clinical and electrographic features of epileptic spasms persisting beyond the second year of life. *Epilepsia*. 2002; 43:623–30. [PubMed: 12060022]
10. Schwartzkroin, PA.; Rho, JM., editors. *Epilepsy, infantile spasms and developmental encephalopathy*. Academic Press; 2002.
11. Fukuyama, Y., editor. *West syndrome and other infantile epileptic encephalopathies*. Elsevier; 2001.

12. Sorel L, Dusaucy-Bauloye A. A propos de 21 cas d'hypsarythmia de Gibbs. Son traitement spectaculaire par l'ACTH. *Acta Neurol Psychiatr Belg*. 1958; 58:130–41. [PubMed: 13532578]
13. de Wied D. Behavioral effects of neuropeptides related to ACTH, MSH, and LPH. *Ann NY Acad Sci*. 1977; 297:263–75. [PubMed: 211902]
14. Pentella K, Bachman DS, Sandman CA. Trial of an ACTH 4–9 analogue in children with intractable seizures. *Neuropediatrics*. 1982; 13:59–62. [PubMed: 6290927]
15. Willig RP, Lagenstein I. Use of ACTH fragments in children with infantile spasms. *Neuropediatrics*. 1982; 13:55–8. [PubMed: 6290926]
16. Snead OC III, Benton JW, Hosey LC, et al. Treatment of infantile spasms with high-dose ACTH: Efficacy and plasma levels of ACTH and prednisone. *Neurol*. 1989; 39:1027–31.
17. Hrachovy RA, Frost JD, Glaze DG. High-dose long-duration versus low-dose short duration corticotropin therapy for infantile spasms. *J Pediatr*. 1994; 124:803–806. [PubMed: 8176573]
18. Baram TZ, Mitchell WG, Tournay A, et al. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. *Pediatrics*. 1996; 97:375–9. [PubMed: 8604274]
19. Hrachovy RA, Frost JD, Kellaway P, Zion TE. Double-blind study of ACTH vs prednisone therapy in infantile spasms. *J Pediatrics*. 1983; 103:641–5.
20. Riikonen RS. Steroids or vigabatrin in the treatment of infantile spasms? *Pediatr Neurol*. 2000; 23:403–8. [PubMed: 11118795]
21. Baram TZ. Pathophysiology of massive infantile spasms: perspective on the putative role of the brain adrenal axis. *Ann Neurol*. 1993; 33:231–6. [PubMed: 8388675]
22. Brunson KL, Khan N, Eghbal-Ahmadi M, Baram TZ. ACTH acts directly on amygdala neurons to down-regulate corticotropin releasing hormone gene expression. *Ann Neurol*. 2001; 49:304–12. [PubMed: 11261504]
23. Schlumberger E, Chavez F, Palacios L, Rey E, Pajot N, Dulac O. Lamotrigine in treatment of 120 children with epilepsy. *Epilepsia*. 1994; 35:359–67. [PubMed: 8156958]
24. Glauser TA, Clark PO, Strawsburg R. A pilot study of topiramate in the treatment of infantile spasms. *Epilepsia*. 1998; 39:1324–8. [PubMed: 9860068]
25. Chiron C, Dulac O, Luna D, Palacios L, Mondragon S, Beaumont D, Mumford JP. Vigabatrin in infantile spasms. *Lancet*. 1990; 335:363–4. [PubMed: 1967808]
26. Vigevano F, Cilio MR. Vigabatrin versus ACTH as first-line treatment for infantile spasms: a randomized, prospective study. *Epilepsia*. 1997; 38:1270–4. [PubMed: 9578521]
27. Elterman RD, Shields WD, Mansfield KA, Nakagawa J. US Infantile Spasms Vigabatrin Study Group. Randomized trial of vigabatrin in patients with infantile spasms. *Neurology*. 2001; 57:1416–21. [PubMed: 11673582]
28. Chiron C, Dumas C, Jambaque I, Mumford J, Dulac O. Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis. *Epilepsy Res*. 1997; 26:389–95. [PubMed: 9095401]
29. Lux AL, Edwards SW, Osborne JP, Hancock E, Johnson AL, Verity CM, Kennedy CR, O'Callaghan FJ, Newton RW. Randomized trial of vigabatrin in patients with infantile spasms. *Neurology*. 2002; 59:648. [PubMed: 12196676]
30. Millichap JG, Ortiz WR. Nitrazepam in myoclonic epilepsies. *Am J Dis Child*. 1966; 112:242–8. [PubMed: 5945538]